INTRODUCTION: Treatment with disease-modifying therapies (DMT) in patients with clinically isolated syndrome (CIS) represents standard care in multiple sclerosis (MS) patients nowadays. Since a proportion of patients may show no evidence of disease activity (NEDA) after some time of treatment, the question might arise about the risks of stopping DMT. METHODS: We present a cohort of 49 patients who started DMT immediately after CIS and had no evidence of disease activity (NEDA-3) for at least five years before discontinuation of therapy. Thereafter, patients underwent clinical and MRI follow-up for at least five consecutive years. RESULTS: Of 49 patients discontinuing DMT, 53% (n = 26) had NEDA for at least further five years, while 47% (n = 23) showed either a relapse/disease progression (18.4%, n = 9), MRI activity (14.3%, n = 7) or both (14.3%, n = 7). The main predictive factor for sustained NEDA was age at DMT termination. Patients aged > 45 years had a significantly lower risk of disease reactivation (13% vs. 54% in patients aged < 45 years, p < 0.001) after DMT discontinuation. DISCUSSION: In CIS patients with immediate DMT after their first clinical episode, older age at the time of DMT discontinuation is the main predictive factor for sustained NEDA status.
INTRODUCTION: Treatment with disease-modifying therapies (DMT) in patients with clinically isolated syndrome (CIS) represents standard care in multiple sclerosis (MS) patients nowadays. Since a proportion of patients may show no evidence of disease activity (NEDA) after some time of treatment, the question might arise about the risks of stopping DMT. METHODS: We present a cohort of 49 patients who started DMT immediately after CIS and had no evidence of disease activity (NEDA-3) for at least five years before discontinuation of therapy. Thereafter, patients underwent clinical and MRI follow-up for at least five consecutive years. RESULTS: Of 49 patients discontinuing DMT, 53% (n = 26) had NEDA for at least further five years, while 47% (n = 23) showed either a relapse/disease progression (18.4%, n = 9), MRI activity (14.3%, n = 7) or both (14.3%, n = 7). The main predictive factor for sustained NEDA was age at DMT termination. Patients aged > 45 years had a significantly lower risk of disease reactivation (13% vs. 54% in patients aged < 45 years, p < 0.001) after DMT discontinuation. DISCUSSION: In CIS patients with immediate DMT after their first clinical episode, older age at the time of DMT discontinuation is the main predictive factor for sustained NEDA status.
Authors: Massimo Filippi; Maria A Rocca; Frederik Barkhof; Wolfgang Brück; Jacqueline T Chen; Giancarlo Comi; Gabriele DeLuca; Nicola De Stefano; Bradley J Erickson; Nikos Evangelou; Franz Fazekas; Jeroen J G Geurts; Claudia Lucchinetti; David H Miller; Daniel Pelletier; Bogdan F Gh Popescu; Hans Lassmann Journal: Lancet Neurol Date: 2012-03-19 Impact factor: 44.182
Authors: Sabine Salhofer-Polanyi; Hakan Cetin; Fritz Leutmezer; Anna Baumgartner; Stephan Blechinger; Assunta Dal-Bianco; Patrick Altmann; Barbara Bajer-Kornek; Paulus Rommer; Michael Guger; Doris Leitner-Bohn; Berthold Reichardt; Farideh Alasti; Wilhelm Temsch; Tanja Stamm Journal: Neuroepidemiology Date: 2017-08-19 Impact factor: 3.282
Authors: L K Fisniku; P A Brex; D R Altmann; K A Miszkiel; C E Benton; R Lanyon; A J Thompson; D H Miller Journal: Brain Date: 2008-01-29 Impact factor: 13.501
Authors: G Comi; V Martinelli; M Rodegher; L Moiola; O Bajenaru; A Carra; I Elovaara; F Fazekas; H P Hartung; J Hillert; J King; S Komoly; C Lubetzki; X Montalban; K M Myhr; M Ravnborg; P Rieckmann; D Wynn; C Young; M Filippi Journal: Lancet Date: 2009-10-06 Impact factor: 79.321
Authors: J T Phillips; P W O'Connor; E Havrdova; M Hutchinson; L Kappos; D H Miller; C H Polman; F D Lublin; G Giovannoni; A Wajgt; F Lynn; M A Panzara; A W Sandrock Journal: Neurology Date: 2006-11-14 Impact factor: 9.910
Authors: W I McDonald; A Compston; G Edan; D Goodkin; H P Hartung; F D Lublin; H F McFarland; D W Paty; C H Polman; S C Reingold; M Sandberg-Wollheim; W Sibley; A Thompson; S van den Noort; B Y Weinshenker; J S Wolinsky Journal: Ann Neurol Date: 2001-07 Impact factor: 10.422
Authors: Tamás Biernacki; Zsófia Kokas; Dániel Sandi; Judit Füvesi; Zsanett Fricska-Nagy; Péter Faragó; Tamás Zsigmond Kincses; Péter Klivényi; Krisztina Bencsik; László Vécsei Journal: Int J Mol Sci Date: 2022-03-21 Impact factor: 5.923